Waters Corporation in the news
Analytical instruments and software
Tamtam found 20 recent articles about Waters Corporation.
- Greater Philadelphia Life Sciences News: INOVIO's $75M Offering, Waters' MOBILion Acquisition & More
Greater Philadelphia's life sciences sector is active with companies raising capital, making acquisitions, and developing workforce talent.
- Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
Waters Corporation obtained FDA clearance for its BD OneFlow LST and BD OneFlow B-CLPD T1 Tests, enabling standardized flow cytometry for diagnosing B-cell non-Hodgkin lymphoma in the U.S.
- Waters Corporation’s (NYSE:WAT) Q3 2026 sales beat estimates, quarterly revenue guidance slightly exceeds expectations
Waters Corporation reported better-than-expected Q3 2026 results with strong revenue growth and raised its full-year EPS guidance.
- What to expect from Waters Corporation’s (WAT) Q3 earnings
Waters Corporation is expected to announce Q3 earnings this Tuesday, with anticipated revenue growth of 119% year-on-year, and positive investor sentiment in the research tools & consumables segment.
- Waters: Integrating Anthropic AI Into Laboratory Workflows
Waters Corporation integrates Anthropic's AI into laboratory workflows to enable researchers to control instruments and manage experiments using natural language, accelerating pharmaceutical research.
- CellCarta Partners with Waters Corporation to Advance Companion Diagnostics and Next-Generation Flow Cytometry
CellCarta partnered with Waters Corporation to advance companion diagnostics and next-generation flow cytometry for biopharmaceutical clients.
- Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation launched Waters AI Link and joined Anthropic's MHS research program to advance AI-enabled LC-MS workflows from research to release.
- Waters Corp. stock outperforms competitors on strong trading day
Waters Corp. stock increased by 1.08% to $433.77, outperforming major market indexes and ending a three-day losing streak.
- Waters Corp. stock outperforms competitors on strong trading day
Waters Corp. stock increased by 1.08% to $433.77 on Friday, ending a three-day losing streak amid a positive market.
- Waters Corporation (WAT) Stock Forecasts
The document provides stock forecasts for Waters Corporation, a company that sells liquid chromatography, mass spectrometry, and thermal analysis tools.
- Waters Corporation stock hits all-time high at 449.0 USD By Investing.com
Waters Corporation's stock reached an all-time high of $449.0 amid strong financial performance and positive analyst revisions, despite concerns about its high P/E ratio and potential overvaluation.
- CellCarta, Waters Corporation collaborate on companion diagnostics
CellCarta and Waters Corporation are collaborating to develop companion diagnostics and flow cytometry solutions for pharmaceutical and biotechnology companies.
- Instead of cash director fees, Heather Knight receives 57.41 stock units at Waters (WAT).
Waters Corporation director Heather Knight received stock units as compensation instead of cash director fees.
- Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
Waters Corporation will host a conference call on November 3, 2026, to discuss its third-quarter 2026 financial results.
- Waters: Positive Momentum Rides High Again (NYSE:WAT)
Waters Corporation's stock has surged on sales growth, yet its earnings guidance has only slightly increased, leading to an elevated valuation.
- How Is Waters Corporation's Stock Performance Compared to Other Health Care Stocks?
Waters Corporation, a provider of analytical workflow solutions, has seen its stock outperform health care benchmarks due to strong demand for lab equipment and strategic initiatives.
- Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Everlywell and Waters Corporation partnered to launch an FDA-cleared at-home HPV cervical cancer screening kit, aiming to improve access and reduce screening gaps.
- Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)
Waters Corporation reported strong Q2 revenue growth, exceeding analyst expectations, driven by industry-leading performance across all divisions.
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
Waters Corporation reported strong Q2 2026 financial results with total revenue of $1.645 billion, organic revenue growth of 7%, and raised its full-year 2026 guidance.
- Waters Corporation Q2 2026 Earnings Call Summary
Waters Corporation reported strong Q2 2026 results with 9% organic growth, accelerated performance in acquired businesses, and raised full-year revenue guidance.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Waters Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies